Azenta (AZTA) has released an update to notify the public and investors about a regulation fd disclosure.
Effective October 1, 2023, Azenta, Inc. restructured into three main business segments: Multiomics, offering genomic analysis services; Sample Management Solutions, providing comprehensive sample management services and products; and B Medical Systems, focused on temperature-controlled storage and transportation solutions for international markets. This realignment aims to drive growth and improve profitability, with changes reflected in the company’s reporting for fiscal years 2023 and 2022.
For further insights into AZTA stock, check out TipRanks’ Stock Analysis page.
For a comprehensive understanding of the announcement, you can read the full document here.
